Diabetes Drugs Linked to Decreased Threat of Dementia

These medicine might efficiently forestall dementia in high-risk people with gentle or average sort 2 diabetes.

In accordance with scientists, it could be value prioritizing these medicine for future reuse analysis.

In accordance with a long-term examine just lately revealed in an open entry journal BMJ Open Diabetes Analysis & Care, utilizing diabetes medicine generally known as glitazones was related to a 22% decrease danger of dementia. Glitazones are sometimes generally known as thiazolidinediones or TZDs for brief and are an older class of sort 2 diabetes medicine.

In accordance with the researchers, these medicine might successfully forestall dementia in high-risk people with gentle to average sort 2 diabetes, and it could now be value prioritizing them in future scientific trials to find out whether or not they can be utilized once more.

Researchers have begun to analyze whether or not diabetes medicine have the potential to assist forestall or treatment dementia since sort 2 diabetes and dementia share some physiological patterns. Nonetheless, the outcomes have been inconsistent to this point.

The researchers in contrast the incidence of dementia in older adults with sort 2 diabetes who obtained both a sulfonylurea or a thiazolidinedione (TZD) with those that obtained metformin alone to shed extra mild on this.

They used information from 559,106 people with sort 2 diabetes who have been recognized within the nationwide Veterans Affairs (VA) Well being System between January 2000 and December 2019.

Solely sufferers who have been older (aged a minimum of 60) and given their first prescription of metformin, a sulfonylurea (tolbutamide, glimepiride, glipizide, or glyburide), or a TZD (rosiglitazone or pioglitazone) between January 2001 and December 2017 have been included (559,106) within the examine. . Their well being was tracked for a mean of virtually 8 years.

After a minimum of 1 yr of drug therapy, TZD use alone was related to a 22% decrease danger of dementia from any trigger, in contrast with metformin use alone.

Particularly, it was related to an 11% decrease danger of[{” attribute=””>Alzheimer’s disease and a 57% lower risk of vascular dementia. Given that vascular diseases increase the risk of Alzheimer’s disease, TZDs may also help to reduce dementia and Alzheimer’s disease in part through their favorable effects on the vascular system, say the researchers.

While the risk of dementia from any cause was 11% lower for the use of metformin and TZD combined, it was 12% higher for the use of a sulfonylurea drug alone, prompting the researchers to suggest that supplementing a sulfonylurea with either metformin or a TZD may partially offset these effects.

Further in-depth analysis indicated that those younger than 75 benefited more from a TZD than older patients, highlighting the importance of early prevention for dementia, note the researchers. And these drugs also seemed to be more protective in overweight or obese patients.

This is an observational study, so definitive conclusions can’t be drawn about cause and effect. And the researchers acknowledge that certain potentially influential information wasn’t available, including kidney function and genetic factors, and that study participants were predominantly male and White.

But they suggest that future studies for repurposing diabetes drugs for dementia prevention might want to consider prioritizing TZDs, based on their findings.

And they conclude: “These findings may help inform medication selection for [older] sufferers with [type 2 diabetes] excessive danger of growing dementia.”

Reference: “Use of oral diabetes medicines and danger of incident dementia in US veterans aged ≥60 years with sort 2 diabetes” by Xin Tang, Roberta Diaz Brinton, Zhao Chen, Leslie V. Farland, Yann Klimentidis, Raymond Migrino, Peter Reaven , Kathleen Rodgers and Jin J Zhou, October 11, 2022, BMJ Open Diabetes Analysis & Care.
DOI: 10.1136/bmjdrc-2022-002894

The examine was funded by the Nationwide Human Genome Analysis Institute, the Nationwide Science Basis, the Nationwide Institute of Diabetes and Digestive and Kidney Ailments, and the Nationwide Coronary heart, Lung, and Blood Institute.

About the author


Leave a Comment